Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib RP, Pastores GM.

Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. doi: 10.1002/14651858.CD006663.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;2:CD006663.

PMID:
20464743
2.

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC.

Cochrane Database Syst Rev. 2016 Jul 25;7:CD006663. doi: 10.1002/14651858.CD006663.pub4. Review.

PMID:
27454104
3.

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib RP, Nascimento P, Pastores GM.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD006663. doi: 10.1002/14651858.CD006663.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;7:CD006663.

PMID:
23450571
4.

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB.

Heart. 2008 Feb;94(2):153-8. Epub 2007 May 4.

PMID:
17483124
5.

Agalsidase alfa: a review of its use in the management of Fabry disease.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. Review.

PMID:
22946754
6.

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, Steiner RD, Beck M, Barshop BA, Rhead W, West M, Martin R, Amato D, Nair N, Huertas P.

Genet Med. 2013 Dec;15(12):983-9. doi: 10.1038/gim.2013.56. Epub 2013 May 16.

PMID:
23680766
7.

Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Schaefer RM, Tylki-Szymańska A, Hilz MJ.

Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Review.

PMID:
19852524
8.

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.

Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO.

Nephrol Dial Transplant. 2006 Feb;21(2):345-54. Epub 2005 Oct 4.

PMID:
16204287
9.

Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.

El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F.

PLoS One. 2017 Mar 15;12(3):e0173358. doi: 10.1371/journal.pone.0173358. eCollection 2017.

10.

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M.

J Inherit Metab Dis. 2003;26(7):617-27.

PMID:
14707510
11.

Fabry disease in children and the effects of enzyme replacement treatment.

Pintos-Morell G, Beck M.

Eur J Pediatr. 2009 Nov;168(11):1355-63. doi: 10.1007/s00431-009-0937-9. Epub 2009 Feb 26.

12.

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.

Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ; Fabry Disease Clinical Trial Study Group.

Ann Intern Med. 2007 Jan 16;146(2):77-86. Epub 2006 Dec 18.

PMID:
17179052
13.

Manual therapy and exercise for adhesive capsulitis (frozen shoulder).

Page MJ, Green S, Kramer S, Johnston RV, McBain B, Chau M, Buchbinder R.

Cochrane Database Syst Rev. 2014 Aug 26;(8):CD011275. doi: 10.1002/14651858.CD011275. Review.

PMID:
25157702
14.

Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.

Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M.

Acta Paediatr. 2007 Jan;96(1):122-7.

PMID:
17187618
15.

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.

Goláň L, Goker-Alpan O, Holida M, Kantola I, Klopotowski M, Kuusisto J, Linhart A, Musial J, Nicholls K, Gonzalez-Rodriguez D, Sharma R, Vujkovac B, Chang P, Wijatyk A.

Drug Des Devel Ther. 2015 Jul 8;9:3435-44. doi: 10.2147/DDDT.S80928. eCollection 2015.

16.

Electrotherapy modalities for adhesive capsulitis (frozen shoulder).

Page MJ, Green S, Kramer S, Johnston RV, McBain B, Buchbinder R.

Cochrane Database Syst Rev. 2014 Oct 1;(10):CD011324. doi: 10.1002/14651858.CD011324. Review.

PMID:
25271097
17.

Fabry disease: overall effects of agalsidase alfa treatment.

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A.

Eur J Clin Invest. 2004 Dec;34(12):838-44.

PMID:
15606727
18.

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.

Lubanda JC, Anijalg E, Bzdúch V, Thurberg BL, Bénichou B, Tylki-Szymanska A.

Genet Med. 2009 Apr;11(4):256-64. doi: 10.1097/GIM.0b013e3181981d82.

PMID:
19265719
19.
20.

Electrotherapy modalities for rotator cuff disease.

Page MJ, Green S, Mrocki MA, Surace SJ, Deitch J, McBain B, Lyttle N, Buchbinder R.

Cochrane Database Syst Rev. 2016 Jun 10;(6):CD012225. doi: 10.1002/14651858.CD012225. Review.

PMID:
27283591

Supplemental Content

Support Center